Showing results (91-100 of 105) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 2005
Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trialC Camps, B Massuti, A Jiménez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 12, 2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)E Grande, J Capdevila, D Castellano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2003
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trialV Alberola, C Camps, M Provencio, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 18, 2017
Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trialA Abad, E Martínez-Balibrea, J M Viéitez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2019
Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapyJ Vidal, B Bellosillo, C Santos Vivas, et al.
British Journal of Cancer|March 6, 2014
LINE-1 methylation in leukocyte DNA, interaction with phosphatidylethanolamine N-methyltransferase variants and bladder cancer riskS M Tajuddin, A F S Amaral, A F Fernández, et al.
European Journal of Cancer (Oxford, England : 1990)|July 28, 2015
PanGen-Fam: Spanish registry of hereditary pancreatic cancerE Mocci, C Guillen-Ponce, J Earl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 23, 2015
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trialC S Fuchs, S Azevedo, T Okusaka, et al.
Pageof 11